Device Trial Radar · NCT07871409
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Jun 16, 2027
Study completion Sep 8, 2027
Sponsor
- Lead sponsor
- AmgenNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
Conditions
- Obesity
- Overweight
Interventions
Maridebart cafraglutideDrug
Administered subcutaneously.
AutoinjectorDevice
The AI will be used by participants to self-administer SC doses of maridebart cafraglutide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home AdministrationTime frame: Weeks 12, 16, and 20
- Percentage of Participants Who Successfully Self-inject a Full Dose Among All Participants Who Entered the Home Self-administration Phase at Each Scheduled Home AdministrationTime frame: Weeks 12, 16, and 20
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Apex Clinical Research
San Diego, California · Recruiting
Southern Clinical Research
Miami, Florida · Recruiting
Research Institute of South Florida
Miami, Florida · Recruiting
22 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.